Patents by Inventor Philippe Lambin
Philippe Lambin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7960114Abstract: The present invention provides methods and compositions for predicting patient responses to cancer treatment using hypoxia gene signatures. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes.Type: GrantFiled: May 1, 2008Date of Patent: June 14, 2011Assignee: Siemens Medical Solutions USA, Inc.Inventors: Renaud G. Seigneuric, Maud H. W. Starmans, Glenn Fung, Balaji Krishnapuram, Dimitry S. A. Nuyten, Arie van Erk, Michael Gaston Magagnin, Kasper M. Rouschop, Sriram Krishnan, R. Bharat Rao, Christoffel Theodorus Anthonius Evelo, Adrian Campbell Begg, Bradly G. Wouters, Philippe Lambin
-
Publication number: 20110059074Abstract: The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes.Type: ApplicationFiled: May 2, 2008Publication date: March 10, 2011Inventors: Maud H.W. Starmans, Balaji Krishnapuram, Ranand G. Seigneuric, Harald Steck, Dimitry S.A. Nuyten, Francesca Buffa, Adrian Lewellyn Harris, Bradly G. Wouters, Philippe Lambin, R. Bharat Rao, Sriram Krishnan
-
Patent number: 7805385Abstract: A predictor of medical treatment outcome is developed and applied. A prognosis model is developed from literature. The model is determined by reverse engineering the literature reported quantities. A relationship of a given variable to a treatment outcome is derived from the literature. A processor may then use individual patient values for one or more variables to predict outcome. The accuracy may be increased by including a data driven model in combination with the literature driven model.Type: GrantFiled: April 16, 2007Date of Patent: September 28, 2010Assignee: Siemens Medical Solutions USA, Inc.Inventors: Harald Steck, Sriram Krishnan, R. Bharat Rao, Philippe Lambin, Cary Dehing-Oberije
-
Publication number: 20100057651Abstract: Knowledge-based interpretable predictive modeling is provided. Expert knowledge is used to seed training of a model by a machine. The expert knowledge may be incorporated as diagram information, which relates known causal relationships between predictive variables. A predictive model is trained. In one embodiment, the model operates even with a missing value for one or more variables by using the relationship between variables. For application, the model outputs a prediction, such as the likelihood of survival for two years of a lung cancer patient. A graphical representation of the model is also output. The graphical representation shows the variables and relationships between variables used to determine the prediction. The graphical representation is interpretable by a physician or other to assist in understanding.Type: ApplicationFiled: July 21, 2009Publication date: March 4, 2010Applicants: Siemens Medicals Solutions USA, Inc., MAASTRO clinicInventors: Glenn Fung, Cary Dehing-Oberije, Andreas Lubbertus Aloysius Johannes Dekker, Philippe Lambin, Shipeng Yu, Kartik Jayasurya Komati
-
Publication number: 20090234627Abstract: Modeling of prognosis of survivability, side-effect, or both is provided. For example, RILI is predicted using bullae information. The amount, volume or ratio of Bullae, even alone, may indicate the likelihood of complication, such as the likelihood of significant (e.g., stage 3) pneumonitis. As another example, RILI is predicted using uptake values of an imaging agent. Standardized uptake from a functional image (e.g., FDG uptake from a positron emission image), alone or in combination with other features, may indicate the likelihood of side-effect. In another example, survivability, such as two-year survivability, is predicted using blood biomarkers. The characteristics of a patient's blood may be measured and, alone or in combination with other features, may indicate the likelihood of survival. The modeling may be for survivability, side-effect, or both and may use one or more of the blood biomarker, uptake value, and bullae features.Type: ApplicationFiled: March 6, 2009Publication date: September 17, 2009Applicants: Siemens Medical Solutions USA, Inc., MAASTRO ClinicInventors: Shipeng Yu, Gelnn Fung, Cary Dehing-Oberije, Dirk de Ruysscher, Sriram Krishnan, R. Bharat Rao, Philippe Lambin
-
Publication number: 20090234626Abstract: Functional imaging information is used to determine a probability of residual disease given a treatment. The functional imaging information shows different characteristic levels for different regions of the tumor. The probability is output for planning use and/or used to automatically determine dose by region. Using the probability, the dose may be distributed by region so that some regions receive a greater dose than other regions. This distribution by region of dose more likely treats the tumor with a same dose, allows a lesser dose to sufficient treat the tumor, and/or allows a greater dose with a lesser or no increase in risk to normal tissue. The dose plan may account for personalized tumors as each patient may have distinct tumors. Probability of dose application accuracy may also be used, so that a combined treatment probability allows efficient dose planning.Type: ApplicationFiled: March 5, 2009Publication date: September 17, 2009Applicant: Siemens Medical Solutions USA, Inc.Inventors: Shipeng Yu, Glenn Fung, Steven Florian Petit, Hugo J.W.L. Aerts, Claudia Offermann, Michel Oellers, Philippe Lambin, Dirk de Ruysscher, Andreas Lubbertus Aloysius Johannes Dekker, Sriram Krishnan
-
Publication number: 20090234628Abstract: A system for modeling complete response prediction is provided. The system includes an input that is operable to receive treatment information representing treatment data that may be used to predict a complete response of a tumor. The complete response may include a disappearance of all or substantially all of a disease. A processor may be operable to use a model to predict complete response of the tumor as a function of the treatment data. The model represents a probability of complete response to treatment given the treatment data. A display is operable to output an image as a function of the complete response prediction.Type: ApplicationFiled: March 10, 2009Publication date: September 17, 2009Applicants: Siemens Medical Solutions USA, Inc., MAASTRO clinicInventors: Shipeng Yu, Glenn Fung, Cary Dehing-Oberije, Lucas Carolus Gertrudis Gerardus Persoon, Sriram Krishnan, R. Bharat Rao, Philippe Lambin, Ruud G.P.M. Van Stiphout, Jeroen Buijsen, Guido Lammering, Marco Janssen, Eric Postma, Vincenzo Valentini
-
Publication number: 20090187522Abstract: A computer-implemented method for privacy-preserving data mining to determine cancer survival rates includes providing a random matrix B agreed to by a plurality of entities, wherein each entity i possesses a data matrix Ai of cancer survival data that is not publicly available, providing a class matrix Di for each of the data matrices Ai, providing a kernel K(Ai, B) by each of said plurality of entities to allow public computation of a full kernel, and computing a binary classifier that incorporates said public full kernel, wherein said classifier is adapted to classify a new data vector according to a sign of said classifier.Type: ApplicationFiled: January 14, 2009Publication date: July 23, 2009Applicant: Siemens Medical Solutions USA, Inc.Inventors: Glenn Fung, R. Bharat Rao, Sriram Krishnan, Shipeng Yu, Cary Dehing-Oberije, Philippe Lambin, Dirk De Ruysscher
-
Publication number: 20090130096Abstract: The present invention provides methods and compositions for predicting patient responses to cancer treatment using hypoxia gene signatures. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes.Type: ApplicationFiled: May 1, 2008Publication date: May 21, 2009Applicant: Siemens Medical Solutions USA, Inc.Inventors: Renaud G. Seigneuric, Maud H.W. Starmans, Glenn Fung, Balaji Krishnapuram, Dimitry S.A. Nuyten, Arie van Erk, Michael Gaston Magagnin, Kasper M. Rouschop, Sriram Krishnan, R. Bharat Rao, Christoffel Theodorus Anthonius Evelo, Adrian Campbell Begg, Bradly G. Wouters, Philippe Lambin
-
Publication number: 20090006055Abstract: A list of biomarkers indicative of patient outcome is reduced. A computer program is applied to a set of biomarkers indicative of a patient outcome (e.g., prognosis, diagnosis, or treatment result). The computer program models the set of biomarkers with a subset of the biomarkers. The subset is identified without labeling based on the patient outcome. Instead, biomarker scores (e.g., sequence score) are used to identify the subset of biomarkers.Type: ApplicationFiled: June 9, 2008Publication date: January 1, 2009Applicant: Siemens Medical solutions USA, Inc.Inventors: Glenn Fung, Renaud G. Seigneuric, Sriram Krishnan, R. Bharat Rao, Philippe Lambin
-
Publication number: 20080286273Abstract: The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes.Type: ApplicationFiled: May 1, 2008Publication date: November 20, 2008Applicant: Siemens Medical Solutions USA, Inc.Inventors: Maud H.W. Starmans, Balaji Krishnapuram, Renaud G. Seigneuric, Harald Steck, Dimitry S.A. Nuyten, Francesca Meteora Buffa, Adrian Lewellyn Harris, Bradly G. Wouters, Philippe Lambin, R. Bharat Rao, Sriram Krishnan
-
Publication number: 20080033894Abstract: A predictor of medical treatment outcome is developed and applied. A prognosis model is developed from literature. The model is determined by reverse engineering the literature reported quantities. A relationship of a given variable to a treatment outcome is derived from the literature. A processor may then use individual patient values for one or more variables to predict outcome. The accuracy may be increased by including a data driven model in combination with the literature driven model.Type: ApplicationFiled: April 16, 2007Publication date: February 7, 2008Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Harald Steck, Sriram Krishnan, R. Rao, Philippe Lambin, Cary Dehing-Oberije
-
Publication number: 20050003357Abstract: The present invention relates a method of converting a promoter into a promoter which is inducible upon genotoxic compounds or conditions. The present invention further relates to a method of reducing the basal expression level of promoter which is inducible upon genotoxic compounds or conditions. These methods provides novel nucleotide sequences, vectors and host cells for the expression of proteins under the control of genotoxic conditons or compounds. The novel expression system has wide industrial applications into the field of recombinant protein production but has also clinical applications such as the controlled expression of therapeutic compounds in hypoxic tissues such as tumors.Type: ApplicationFiled: June 21, 2002Publication date: January 6, 2005Inventors: Jozef Anne, Sandra Nuyts, Philippe Lambin